These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 35442700)

  • 21. Dual target PARP1/EZH2 inhibitors inducing excessive autophagy and producing synthetic lethality for triple-negative breast cancer therapy.
    Li X; Wang C; Li S; Yin F; Luo H; Zhang Y; Luo Z; Chen Y; Wan S; Kong L; Wang X
    Eur J Med Chem; 2024 Feb; 265():116054. PubMed ID: 38134746
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of base excision repair key factors and miR17 in familial and sporadic breast cancer.
    De Summa S; Pinto R; Pilato B; Sambiasi D; Porcelli L; Guida G; Mattioli E; Paradiso A; Merla G; Micale L; De Nittis P; Tommasi S
    Cell Death Dis; 2014 Feb; 5(2):e1076. PubMed ID: 24556691
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.
    Boerner JL; Nechiporchik N; Mueller KL; Polin L; Heilbrun L; Boerner SA; Zoratti GL; Stark K; LoRusso PM; Burger A
    PLoS One; 2015; 10(3):e0119614. PubMed ID: 25774912
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of a novel dual-target inhibitor of CDK12 and PARP1 that induces synthetic lethality for treatment of triple-negative breast cancer.
    Zhang L; Zhen Y; Feng L; Li Z; Lu Y; Wang G; Ouyang L
    Eur J Med Chem; 2023 Nov; 259():115648. PubMed ID: 37478560
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibition.
    Xia Q; Cai Y; Peng R; Wu G; Shi Y; Jiang W
    Int J Oncol; 2014 Mar; 44(3):735-44. PubMed ID: 24378347
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality.
    Papadimitriou M; Mountzios G; Papadimitriou CA
    Cancer Treat Rev; 2018 Jun; 67():34-44. PubMed ID: 29753961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combining Data-Driven and Structure-Based Approaches in Designing Dual PARP1-BRD4 Inhibitors for Breast Cancer Treatment.
    Feng B; Yu H; Dong X; Díaz-Holguín A; Antolin AA; Hu H
    J Chem Inf Model; 2024 Oct; 64(19):7725-7742. PubMed ID: 39292752
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
    Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K
    Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resurrection of PARP Inhibitors in Breast Cancer.
    Lyons TG; Robson ME
    J Natl Compr Canc Netw; 2018 Sep; 16(9):1150-1156. PubMed ID: 30181424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.
    Gogola E; Duarte AA; de Ruiter JR; Wiegant WW; Schmid JA; de Bruijn R; James DI; Guerrero Llobet S; Vis DJ; Annunziato S; van den Broek B; Barazas M; Kersbergen A; van de Ven M; Tarsounas M; Ogilvie DJ; van Vugt M; Wessels LFA; Bartkova J; Gromova I; Andújar-Sánchez M; Bartek J; Lopes M; van Attikum H; Borst P; Jonkers J; Rottenberg S
    Cancer Cell; 2018 Jun; 33(6):1078-1093.e12. PubMed ID: 29894693
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of dual PARP and CDK6 inhibitors for triple-negative breast cancer with wild-type BRCA.
    Wang C; Luo H; Chen X; Zhang Y; Lu D; Liu X; Yin F; Li S; Kong L; Wang X
    Bioorg Chem; 2023 Oct; 139():106683. PubMed ID: 37379778
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BRCAness, Homologous Recombination Deficiencies, and Synthetic Lethality.
    Murai J; Pommier Y
    Cancer Res; 2023 Apr; 83(8):1173-1174. PubMed ID: 37057596
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells.
    Sullivan-Reed K; Bolton-Gillespie E; Dasgupta Y; Langer S; Siciliano M; Nieborowska-Skorska M; Hanamshet K; Belyaeva EA; Bernhardy AJ; Lee J; Moore M; Zhao H; Valent P; Matlawska-Wasowska K; Müschen M; Bhatia S; Bhatia R; Johnson N; Wasik MA; Mazin AV; Skorski T
    Cell Rep; 2018 Jun; 23(11):3127-3136. PubMed ID: 29898385
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of Potent and Novel Dual PARP/BRD4 Inhibitors for Efficient Treatment of Pancreatic Cancer.
    Wang SP; Li Y; Huang SH; Wu SQ; Gao LL; Sun Q; Lin QW; Huang L; Meng LQ; Zou Y; Zhu QH; Xu YG
    J Med Chem; 2021 Dec; 64(23):17413-17435. PubMed ID: 34813314
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer.
    Luo J; Jin J; Yang F; Sun Z; Zhang W; Shi Y; Xu J; Guan X
    Int J Biol Sci; 2016; 12(12):1500-1510. PubMed ID: 27994514
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, synthesis and mechanism studies of novel dual PARP1/BRD4 inhibitors against pancreatic cancer.
    Huang SH; Cao R; Lin QW; Wu SQ; Gao LL; Sun Q; Zhu QH; Zou Y; Xu YG; Wang SP
    Eur J Med Chem; 2022 Feb; 230():114116. PubMed ID: 35091172
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V; Illuzzi G; Héberlé E; Dantzer F
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Novel Inhibitor of Poly(
    Jin Y; Wang L; Jin C; Zhang N; Shimizu S; Xiao W; Guo C; Liu X; Si H
    Chem Res Toxicol; 2024 Apr; 37(4):561-570. PubMed ID: 38534178
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthetic Lethality - Its Current Application and Potential in Oncological Treatment.
    Bortlíková L; Müller P; Vojtěšek B; Rak V; Svoboda M
    Klin Onkol; 2019; 32(Supplementum 3):19-24. PubMed ID: 31627702
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.